Benchmark against your competition
Understand how AI crawlers access your site
See where AI gets info about you
Track the queries mentioning your brand
Own your AI narrative
Add GEO to your service offerings
Get recommended in shopping queries
Monitor AI mentions at scale
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT)
What AI says about Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT)
Arcutis Biotherapeutics is dedicated to advancing treatment options for immune-mediated skin diseases through meaningful innovation. Their flagship product, ZORYVE, simplifies disease management for conditions like plaque psoriasis and atopic dermatitis.
Is this your brand?
Claim this profile to keep your information accurate and add what's missing.
Products & Services
ZORYVE
A next-generation small molecule inhibitor of phosphodiesterase-4 (PDE4) available in a steroid-free topical cream, indicated for the treatment of plaque psoriasis and atopic dermatitis.
Common Questions
What conditions does ZORYVE treat?
ZORYVE is indicated for the treatment of plaque psoriasis and atopic dermatitis in patients aged 2 years and older.
Is ZORYVE safe for children?
Yes, ZORYVE is indicated for use in pediatric patients aged 2 years and older for atopic dermatitis.
How does ZORYVE work?
ZORYVE works as a small molecule inhibitor of phosphodiesterase-4 (PDE4), which helps to simplify disease management in patients with chronic inflammatory skin conditions.
What support programs does Arcutis offer?
Arcutis offers ZORYVE Direct for prescription updates and refill reminders, and the Arcutis Cares program for eligible uninsured or underinsured patients.
What is the pricing model for ZORYVE?
Arcutis is committed to responsible pricing and offers programs to help patients with out-of-pocket costs.